



**November 3, 2023**

Roche Diagnostics  
Attention: Cynthia Aker  
9115 Hague Road  
Indianapolis, IN 46250

Re: **BK230840**

Trade/Device Name: Elecsys Anti-CMV  
PreciControl Anti-CMV  
PreciControl Release Anti-CMV  
Regulation Number: 21 CFR 866.3175  
Regulation Name: Cytomegalovirus serological reagents  
Regulatory Class: Class II  
Product Code: MZE  
Dated: September 25, 2023  
Received: September 25, 2023

Dear Cynthia Aker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the **Federal Register**.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act, or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Hira Nakhasi, PhD  
Director  
Division of Emerging and Transfusion  
Transmitted Diseases  
Office of Blood Research and Review  
Center for Biologics Evaluation and Research

Enclosure: Indications for Use

### Indications for Use

**510(k) Number:** BK 230840

**Device Name:** Elecsys Anti-CMV  
PreciControl Anti-CMV  
PreciControl Release Anti-CMV

#### Indications for Use:

##### **Elecsys Anti-CMV**

Elecsys Anti-CMV is an in vitro immunoassay for the qualitative detection of antibodies to Cytomegalovirus in human serum and plasma. Elecsys Anti-CMV is intended to screen individual human donors, including volunteer donors of whole blood, and blood components. This test is also intended to be used to screen organ, tissue and cell donors, when donor samples are obtained while the donor's heart is still beating. It is not intended for use on cord blood specimens.

The electrochemiluminescence immunoassay "ECLIA" is intended for use with **cobas pro** serology solution equipped with the **cobas e 801** analytical unit.

##### **PreciControl Anti-CMV**

PreciControl Anti-CMV is used for quality control of the Elecsys Anti-CMV immunoassay on **cobas pro** serology solution.

##### **PreciControl Release Anti-CMV**

PreciControl Release Anti-CMV is used to validate the **cobas pro** serology solution and to release sample results for the Elecsys Anti-CMV immunoassay. The recovery of the release control within Roche specified limits ensures the specified sensitivity of the assay under customer site conditions.

The release control is tested at user-defined intervals with a maximum span of every 300 samples or 350 determinations and must be tested in order to release the test results. For release control values that fall outside the defined limits, samples measured before a failed release control are flagged as invalid by the **cobas pro** serology controller and need to be repeated. Reactive results will not be invalidated by a failed release control and must be retested in duplicate.

Prescription Use  X  AND/OR  
(Part 21 CFR 801 Subpart D)

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CBER, Office of Blood Research and Review (OBRR)

\_\_\_\_\_  
Division Sign-Off, Office of Blood Research and Review